Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA.
Oncogene. 2010 Apr 22;29(16):2337-45. doi: 10.1038/onc.2009.516. Epub 2010 Jan 25.
An oncogenic mutation (G49A:E17K) in the AKT1 gene has been described recently in human breast, colon, and ovarian cancers. The low frequency of this mutation and perhaps other selective pressures have prevented the isolation of human cancer cell lines that harbor this mutation thereby limiting functional analysis. Here, we create a physiologic in vitro model to study the effects of this mutation by using somatic cell gene targeting using the nontumorigenic human breast epithelial cell line, MCF10A. Surprisingly, knock in of E17K into the AKT1 gene had minimal phenotypic consequences and importantly, did not recapitulate the biochemical and growth characteristics seen with somatic cell knock in of PIK3CA hotspot mutations. These results suggest that mutations in critical genes within the PI3-kinase (PI3K) pathway are not functionally equivalent, and that other cooperative genetic events may be necessary to achieve oncogenic PI3K pathway activation in cancers that contain the AKT1 E17K mutation.
最近在人类乳腺癌、结肠癌和卵巢癌中描述了 AKT1 基因的致癌突变(G49A:E17K)。这种突变的低频率和其他选择性压力可能阻止了携带有这种突变的人类癌细胞系的分离,从而限制了功能分析。在这里,我们使用非致瘤性人乳腺上皮细胞系 MCF10A 进行体细胞基因靶向,创建了一个生理体外模型来研究这种突变的影响。令人惊讶的是,E17K 敲入 AKT1 基因几乎没有表型后果,重要的是,它没有重现体细胞敲入 PIK3CA 热点突变时观察到的生化和生长特征。这些结果表明,PI3-激酶(PI3K)通路中关键基因的突变在功能上并不等同,并且在含有 AKT1 E17K 突变的癌症中,可能需要其他协同的遗传事件来实现致癌的 PI3K 通路激活。